Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 274 Cr.
- Current Price ₹ 185
- High / Low ₹ 326 / 182
- Stock P/E 37.7
- Book Value ₹ 49.8
- Dividend Yield 0.54 %
- ROCE 13.5 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 19.4%
Cons
- The company has delivered a poor sales growth of 7.26% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
17.83 | 15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 75.22 | |
16.63 | 14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 63.80 | |
Operating Profit | 1.20 | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 11.42 |
OPM % | 6.73% | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 15.18% |
0.29 | 0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.56 | |
Interest | 0.43 | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 0.76 |
Depreciation | 0.44 | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 2.42 |
Profit before tax | 0.62 | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 9.80 |
Tax % | 29.03% | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | |
0.44 | 0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 7.26 | |
EPS in Rs | 0.81 | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 4.91 |
Dividend Payout % | 0.00% | 0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 7% |
3 Years: | 14% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 34% |
5 Years: | -3% |
3 Years: | -2% |
TTM: | -28% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 42% |
3 Years: | 14% |
1 Year: | -34% |
Return on Equity | |
---|---|
10 Years: | 24% |
5 Years: | 23% |
3 Years: | 21% |
Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.80 | 1.80 | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 | 14.81 |
Reserves | 3.56 | 4.00 | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 57.45 | 58.95 |
3.75 | 3.46 | 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 26.46 | 28.71 | |
4.01 | 4.53 | 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 12.38 | 11.15 | 13.98 | |
Total Liabilities | 13.12 | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 116.45 |
6.12 | 6.94 | 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 33.09 | 56.58 | |
CWIP | 0.54 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.31 | 21.06 | 1.97 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 19.83 | 20.58 |
6.41 | 6.80 | 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 43.01 | 35.89 | 37.32 | |
Total Assets | 13.12 | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 116.45 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.73 | 1.18 | 1.52 | 0.83 | 1.41 | 3.50 | 8.05 | 10.90 | 9.62 | 9.14 | 14.82 | 16.54 | |
-0.90 | -0.66 | -0.72 | -0.97 | -1.45 | -4.17 | -5.18 | -7.62 | -8.16 | -2.64 | -20.48 | -25.85 | |
-0.08 | -0.64 | -0.29 | -0.07 | 1.94 | -0.07 | -1.23 | -3.56 | -0.76 | 2.76 | 0.96 | 7.40 | |
Net Cash Flow | -0.25 | -0.11 | 0.51 | -0.22 | 1.90 | -0.74 | 1.64 | -0.29 | 0.69 | 9.26 | -4.70 | -1.91 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 35.62 | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 |
Inventory Days | 107.00 | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 |
Days Payable | 80.05 | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 83.28 |
Cash Conversion Cycle | 62.57 | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 87.52 |
Working Capital Days | 44.01 | 60.79 | 34.82 | 56.87 | 56.55 | 57.68 | 49.20 | 52.48 | 70.77 | 68.54 | 79.83 | 76.94 |
ROCE % | 11.35% | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 2d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Newspaper Publication of Unaudited Financial Results for the Quarter and Half Year ended 30th September 2024
-
Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2024
11 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th November 2024
11 Nov - Approved unaudited financial results for Q2 FY 2024-25.
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries